Cutting edge: Engineering active IKKb in T cells drives tumor rejection

Journal of Immunology

Volumn 196, Issue 7, 2016, Pages 2933-2938

  Evaristo, César ^a,b   Spranger, Stefani ^a   Barnes, Sarah E ^a   Miller, Michelle L ^a   Molinero, Luciana L ^a,c   Locke, Frederick L ^a,d   Gajewski, Thomas F ^a   Alegre, Maria Luisa ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Institut für Experimentelle Immunologie   (Germany)

^c GENENTECH INC   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TAMOXIFEN; I KAPPA B KINASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; EFFECTOR CELL; GROWTH INHIBITION; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REJECTION; ANIMAL; BIOSYNTHESIS; CYTOTOXICITY; DISEASE MODEL; GENE EXPRESSION; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC ENGINEERING; HETEROGRAFTS; HUMANS; I-KAPPA B KINASE; INTERFERON-GAMMA; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, TRANSGENIC; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84962485292     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501144     Document Type: Article

References (36)

1. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4 (+) T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368.
2. Mlecnik, B., M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea, T. Meatchi, P. Bruneval, Z. Trajanoski, W. H. Fridman, F. Pagès, and J. Galon. 2011. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29:610-618.
3. + T-cell recruitment. Cancer Res. 69:3077-3085.
4. Ulloa-Montoya, F., J. Louahed, B. Dizier, O. Gruselle, B. Spiessens, F. F. Lehmann, S. Suciu, W. H. Kruit, A. M. Eggermont, J. Vansteenkiste, and V. G. Brichard. 2013. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31:2388-2395.
5. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213.
6. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Liénard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-2873.
7. + T cells in the circulation but not in the tumor site. J. Immunol. 177:1670-1678.
8. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63:2535-2545.
9. Harlin, H., T. V. Kuna, A. C. Peterson, Y. Meng, and T. F. Gajewski. 2006. Tumor progression despite massive influx of activated CD8 (+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55:1185-1197.
10. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723.
11. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736.
12. Hamid, O., C. Robert, A. Daud, F. S. Hodi, W.-J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134-144.
13. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, M. K. Cathcart, T. Bloom, A. C. Novick, R. M. Bukowski, T. Hamilton, and J. H. Finke. 1999. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J. Clin. Invest. 104:769-776.
14. Simpson-Abelson, M. R., J. L. Loyall, H. K. Lehman, J. L. Barnas, H. Minderman, K. L. O'Loughlin, P. K. Wallace, T. C. George, P. Peng, R. J. Kelleher, Jr., et al. 2013. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kB and NFAT signaling in tumor-associated T cells. Cancer Immun. 13:14.
15. Uzzo, R. G., P. E. Clark, P. Rayman, T. Bloom, L. Rybicki, A. C. Novick, R. M. Bukowski, and J. H. Finke. 1999. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J. Natl. Cancer Inst. 91:718-721.
16. Broderick, L., S. P. Brooks, H. Takita, A. N. Baer, J. M. Bernstein, and R. B. Bankert. 2006. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin. Immunol. 118:159-169.
17. Barnes, S. E., Y. Wang, L. Chen, L. L. Molinero, T. F. Gajewski, C. Evaristo, and M.-L. Alegre. 2015. T cell-NF-kB activation is required for tumor control in vivo. J. Immunother. Cancer 3:1.
18. Wan, Y. Y., R. P. Leon, R. Marks, C. M. Cham, J. Schaack, T. F. Gajewski, and J. De Gregori. 2000. Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc. Natl. Acad. Sci. USA 97:13784-13789.
19. Matsuda, T., and C. L. Cepko. 2007. Controlled expression of transgenes introduced by in vivo electroporation. Proc. Natl. Acad. Sci. USA 104:1027-1032.
20. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17:737-747.
21. Vilimas, T., J. Mascarenhas, T. Palomero, M. Mandal, S. Buonamici, F. Meng, B. Thompson, C. Spaulding, S. Macaroun, M.-L. Alegre, et al. 2007. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 13:70-77.
22. Engels, B., H. Cam, T. Schüler, S. Indraccolo, M. Gladow, C. Baum, T. Blankenstein, and W. Uckert. 2003. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14:1155-1168.
23. Correa, M. R., A. C. Ochoa, P. Ghosh, H. Mizoguchi, L. Harvey, and D. L. Longo. 1997. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158:5292-5296.
24. Ghosh, P., A. Sica, H. A. Young, J. Ye, J. L. Franco, R. H. Wiltrout, D. L. Longo, N. R. Rice, and K. L. Komschlies. 1994. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res. 54:2969-2972.
25. Molinero, L. L., M. L. Miller, C. Evaristo, and M. L. Alegre. 2011. High TCR stimuli prevent induced regulatory T cell differentiation in a NF-kB-dependent manner. J. Immunol. 186:4609-4617.
26. Dunn, G. P., H. Ikeda, A. T. Bruce, C. Koebel, R. Uppaluri, J. Bui, R. Chan, M. Diamond, J. M. White, K. C. Sheehan, and R. D. Schreiber. 2005. Interferongamma and cancer immunoediting. Immunol. Res. 32:231-245.
27. Kline, J., L. Zhang, L. Battaglia, K. S. Cohen, and T. F. Gajewski. 2012. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J. Immunol. 188:2630-2642.
28. Lee, P. P., D. R. Fitzpatrick, C. Beard, H. K. Jessup, S. Lehar, K. W. Makar, M. Pérez-Melgosa, M. T. Sweetser, M. S. Schlissel, S. Nguyen, et al. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15:763-774.
29. Krishna, S., D. Xie, B. Gorentla, J. Shin, J. Gao, and X. P. Zhong. 2012. Chronic activation of the kinase IKKb impairs T cell function and survival. J. Immunol. 189:1209-1219.
30. Hu, M. C., D.-F. Lee, W. Xia, L. S. Golfman, F. Ou-Yang, J.-Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, et al. 2004. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:225-237.
31. Schmid, J. A., and A. Birbach. 2008. IkappaB kinase b (IKKbeta/IKK2/IKBKB)-a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev. 19:157-165.
32. Curti, B. D., and W. J. Urba. 2015. Clinical deployment of antibodies for treatment of melanoma. Mol. Immunol. 67(2 Pt. A):18-27.
33. Chen, L., Y. Hussien, K. W. Hwang, Y. Wang, P. Zhou, and M. L. Alegre. 2008. Overexpression of program death-1 in T cells has mild impact on allograft survival. Transpl. Int. 21:21-29.
34. Harlin, H., K. W. Hwang, D. A. Palucki, O. Kim, C. B. Thompson, M. Boothby, and M. L. Alegre. 2002. CTLA-4 engagement regulates NF-kappaB activation in vivo. Eur. J. Immunol. 32:2095-2104.
35. Martinez-Forero, I., A. Azpilikueta, E. Bolaños-Mateo, E. Nistal-Villan, A. Palazon, A. Teijeira, G. Perez-Chacon, A. Morales-Kastresana, O. Murillo, M. Jure-Kunkel, et al. 2013. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J. Immunol. 190:6694-6706.
36. Gajewski, T. F. 2012. Cancer immunotherapy. Mol. Oncol. 6:242-250.